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Abstract
Background: Most pancreatic ductal adenocarcinoma patients present with advanced disease. Whether it is possible to
increase survival by earlier diagnosis is unclear.
Objective: The purpose of this study was to investigate the association between presenting complaints and risk factors for
pancreatic cancer with diagnostic delay, stage and survival.
Methods: This was a single-centre retrospective cohort study. Consecutive patients were interviewed and data on demo-
graphics, medical history, risk factors and complaints leading to pancreatic ductal adenocarcinoma diagnosis and disease
stage were recorded. Diagnostic delay was considered as time between first complaint and diagnosis. Patients received
appropriate treatments and their outcome was recorded in a dedicated database. The Chi-square test for comparison of
categorical variables and the Mann–Whitney test for continuous variables were employed with Bonferroni corrections.
Correlation between continuous variables was evaluated by means of the Spearman correlation coefficient. Survival analysis
was performed with the Kaplan–Meier method and a log-rank test.
Results: The median diagnostic delay for 477 pancreatic ductal adenocarcinoma patients was two months (interquartile
range 1–5), being significantly shorter for patients presenting with jaundice compared with those with pain, weight loss,
diabetes (p< 0.001). The global rate of metastatic disease at diagnosis was 40%, being only 22% in those presenting with
jaundice. The median diagnostic delay, however, was not significantly different among disease stages but was significantly
longer in patients with a body mass index>25 kg/m2. The median survival time was seven months. Factors associated with
worse survival at the multivariable analysis were older age (hazard ratio 1.02 per year), metastatic disease (hazard ratio
2.12) and pain as presenting complaint (hazard ratio 1.32), while diagnostic delay was not.
Conclusion: While some complaints are associated with a shorter diagnostic delay and less advanced disease stage, we
could not demonstrate that delay is associated with survival, possibly suggesting that prevention rather than early recog-
nition is important to tackle pancreatic cancer lethality.
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Key summary
Summarise the established knowledge on this subject
. Pancreatic ductal adenocarcinoma (PDAC) is a lethal disease, and is usually diagnosed at advanced stages
not amenable to curative treatments. Most complaints caused by PDAC are unspecific and might not be
recognised promptly, leading to diagnostic delay.
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. A shorter delay between the first presenting complaints and the detection of the disease should help
in improving the prognosis of PDAC patients, but data on the association between presenting com-
plaints, diagnostic delay, disease stage and survival in patients with PDAC are extremely limited and
heterogeneous.
. Awareness campaigns also underline the role of risk factors for PDAC occurrence, such as family history
of PDAC, smoking, diabetes, overweight or obesity and excessive alcohol consumption. It is, therefore,
conceivable that subjects carrying these risk factors require more prompt investigation, but to the best of
our knowledge, there are no data investigating whether these factors might influence the diagnostic delay
and, hence, the stage of the disease at diagnosis and its prognosis.
. The aim of this study was to investigate the association between presenting complaints of the disease, the
diagnostic delay and tumour stage at time of diagnosis and survival. The secondary aim was to evaluate
whether risk factors for PDAC occurrence are associated with its presentation, with the disease stage at
diagnosis and with survival.
What are the significant and/or new findings of this study?
. In the largest cohort of 477 PDAC patients for a study of this kind, we found that while some presenting
complaints, such as jaundice, have a lower diagnostic delay with a lower rate of metastatic disease, the
hypothesis that diagnostic delay is associated with survival was rejected.
. Among the investigated risk factors for PDAC, overweight was associated with an increased diagnostic
delay.
. Factors associated with worse survival at the multivariable analysis were older age, metastatic disease
at diagnosis and pain as presenting complaint, while an association with diagnostic delay was
not confirmed.
. These data support the view that prevention rather than early recognition is important to tackle PDAC
lethality as the disease is too aggressive when complaints appear.
Background
Pancreatic ductal adenocarcinoma (PDAC) is the 12th
most common cancer worldwide1 and currently the
third leading cause of cancer-related death,2 but projec-
tions to 2030 estimate that it will become the second
leading cause.3 The prognosis of patients with PDAC is
poor, with a five-year survival rate of only about 8%.4
This is mainly due to the fact that most patients present
with advanced disease not amenable to surgical resec-
tion, which remains the only potentially curative treat-
ment.5 Indeed, outside of screening programmes that
are currently limited to research protocols conducted
on small populations of high-risk individuals,6,7 the dis-
ease is usually diagnosed as a result of signs and symp-
toms that are often unspecific and unrecognised,
possibly determining diagnostic delay. The key ques-
tion concerning early detection is whether or not it is
possible to increase survival by identifying those
patients whose complaints and risk factors suggest a
diagnosis of PDAC.
The most common presenting complaints of PDAC
are obstructive jaundice, abdominal pain, new-onset dia-
betes and weight loss.8 While jaundice is strictly related
to the site of the disease in the head of the pancreas and
usually leads to early referral for evaluation of the biliary
tract and the pancreas, the other complaints might be
subtle and often lead to other investigations or medical
care that are not focused on the pancreas.9
Campaigns aimed at increasing the awareness of the
population and of primary care physicians toward the
initial symptoms of PDAC have been undertaken with
the aim of allowing diagnosis at early stages of the dis-
ease.10 However, although one can intuitively hypothe-
sise that a shorter delay between the first presenting
complaints and the detection of the disease should
help in improving the prognosis of PDAC patients,
data on the association between presenting complaints,
diagnostic delay, disease stage and survival in patients
with PDAC are extremely limited and heteroge-
neous.11,12 Awareness campaigns also underline the
role of risk factors for PDAC occurrence, such as
family history of PDAC smoking, diabetes, overweight
or obesity and excessive alcohol consumption.10,13 It is,
therefore, conceivable that subjects with these risk fac-
tors require more prompt investigation, but to the best
of our knowledge, there are no data investigating
whether these factors might influence the diagnostic
delay and, hence, the stage of the disease at diagnosis
and its prognosis.
The primary aim of the present study was to inves-
tigate the association between presenting complaints of
the disease, the diagnostic delay and tumour stage at
time of diagnosis and survival.
The secondary aim was to evaluate whether risk fac-
tors for PDAC occurrence are associated with its pres-
entation, with the disease stage at diagnosis and with
survival.
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Patients and methods
Study design
A retrospective, single centre cohort study was conducted
at the Digestive and Liver Disease Unit of S. Andrea
Hospital, University Sapienza of Rome, Italy. All con-
secutive patients with histologically confirmed PDAC,
prospectively recorded between July 2005–April 2018,
were enrolled upon institutional review board approval
of a database of pancreatic cancer clinical data (protocol
number 251/2012). Written, informed consent was
obtained from each patient included in the study. The
study protocol conforms to the ethical guidelines of the
1975 Declaration of Helsinki.
Patients were interviewed at the time of diagnosis
by trained medical doctors who filled in a specific
questionnaire to collect data on demographics, medical
history, risk factors and symptoms or signs that led to
PDAC diagnosis. No proxies were interviewed.
Investigated risk factors
The following variables were collected: sex, age,
tobacco and alcohol intake, body mass index (BMI),
family history of cancer and history of diabetes, as
previously described.14 Ever smokers were defined as
subjects reporting >6 months of smoking or >100 cig-
arettes smoked during their lifetime. The following data
about smoking were recorded for each patient: age at
smoking initiation, mean daily number of smoked cig-
arettes and total years of smoking. For former smokers,
the number of years since quitting smoking was also
recorded. Ever-alcohol drinkers were defined as such
if they drank at least a mean of 12.5 g of alcohol per
day for at least one year, or a lower amount for
>1 year. One glass of wine, one pint (or can) of beer
and one shot of hard liquor were all considered equal to
one alcohol unit (12.5 g of alcohol). The number of
mean alcohol units per day drunk by patients was rec-
orded. Subjects were asked about the cancer history of
first- and second-degree relatives’. When available, data
on the number of family members with cancer, type(s)
of cancer and age at cancer diagnosis were recorded.
Presenting complaints
As far as presenting complaints are concerned, the
patients were asked about the very first complaint
they could recall preceding the diagnosis. Specifically,
they were asked whether they had experienced jaundice,
weight loss (of at least 5 kg or of 5% or their usual adult
weight), significant epigastric and/or back pain, new-
onset diabetes (diagnosed within the 12 months before
diagnosis) or other symptoms. In cases where no com-
plaints were reported and the lesion was diagnosed
during imaging procedures performed for other indica-
tions, the diagnosis was deemed incidental. Patients
diagnosed during specific surveillance protocols for
high-risk individuals were excluded. The symptoms
and signs were considered the first complaint by the
time of first presentation and not by their severity or
request of first medical observation, as previously
reported.15 The diagnostic delay was considered as
the time between the first reported complaint and the
histological diagnosis of PDAC.
Tumour stage and patients’ outcome
Data about tumour stage at diagnosis were also rec-
orded and patients were classified accordingly as with:
(a) resectable disease, (b) locally advanced or borderline
resectable, (c) metastatic disease as defined previ-
ously.16 Patients received appropriate medical treat-
ments and their outcome was recorded in a dedicated
prospective database.
Statistical analysis
Continuous variables are presented as mean (stand-
ard deviation (SD)) when the distribution is not skewed
or as median and interquartile range (IQR; 25th–75th
percentiles) if the distribution is skewed.
Chi square was employed for comparison of categor-
ical variables, and the Mann–Whitney test for continu-
ous variables with post-hoc Bonferroni correction for
pairwise comparisons. Correlation between continuous
variables was evaluated by means of the Spearman cor-
relation coefficient. Overall survival (OS) was defined as
the time between diagnosis and date of death. Survival
analysis was performed using the Kaplan–Meier
method, and the results were compared using a log-
rank test. Risk factors were expressed as hazard ratio
(HR) (95% confidence interval (CI)). The analysis of
risk factors for prediction of survival was performed
with univariable and multivariable analysis using a
Cox proportional hazards regression model. The multi-
variable model was constructed by the ‘enter’ method,
after including all variables which had significant
results in the univariable analysis. Tests of statistical
significance and confidence intervals were two-sided; a
value of p< 0.05 was considered to be statistically sig-
nificant. A dedicated software (Medcalc 12.1, Belgium)
was used throughout the study.
Results
Study cohort
Of 512 consecutive patients seen in the study period, 10
(1.9%) were not histologically confirmed, seven (1.4%)
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refused to be interviewed and six (1.1%) were too ill to
take part and provide information and were therefore
excluded; 12 patients (2.3%) with a follow-up shorter
than three months were also excluded. The participation
rate was therefore 93%, and the final study population
consisted of 477 PDAC cases. Their mean age was 68
years (11.3), 245 (51.4%) were males. Concerning the
disease stage at diagnosis, 144 (30.5%) had a resectable
disease, 140 (29.5%) had a locally advanced or border-
line resectable disease and the majority had a distant
metastasis (190 patients, 40%).
Regarding the distribution of major risk factors for
pancreatic cancer, 298 (62.5%) were ever-smokers, 283
(62.2%) had a BMI>25, 214 (44.9%) were ever-alcohol
drinkers, 74 (15.5%) had a previous history of diabetes
mellitus type II and 39 (8.2%) had a first degree family
history of PDAC (see Table 1).
Association between presenting complaints,
diagnostic delay and stage
Disease presented with jaundice in 77 (16.2%) patients,
with weight loss in 178 (37.6%) patients, with pain
in 119 (25.1%) patients, and new onset diabetes was
the first complaint in 45 (9.5%) cases. A minority of
cases (26, 5.5%) reported other less specific complaints
and 29 (6.1 %) had incidental diagnosis (see Table 2).
When the relationship between the first presenting
complaint and stage at diagnosis was analysed, the
results suggested a significant association (Chi square
test, p¼ 0.001 with contingency coefficient 0.215). In
detail, when performing pairwise comparisons between
the rate of patients with jaundice presenting with meta-
static disease at the time of diagnosis and the other
five subgroups of presenting complaints (Bonferroni
correction, 0.05/5¼ 0.01), the results were significantly
different between the subgroup of patients with
jaundice compared with those presenting with pain
(p¼ 0.00004) or with weight loss (p¼ 0.0011), but not
compared with those with incidental diagnosis
(p¼ 0.44) or diabetes (p¼ 0.13) or other complaints
(p¼ 0.12).
We also performed a logistical regression analysis
with metastatic disease at diagnosis as outcome and
the different presenting complaints as explanatory vari-
ables and while jaundice (odds ratio (OR) 0.36; 95% CI
0.20–0.65) was associated with a decreased risk of meta-
static disease, and pain with an increased risk (OR 1.84;
95% 1.21–2.80), all other presenting complaints were
not significantly associated with metastatic disease.
Overall, the median diagnostic delay was two months
(1–5). The median diagnostic delay (see Table 2) was
different among the subgroups with different presenting
complaints (incidental diagnosis were excluded from this
comparison), being significantly shorter for patients pre-
senting with jaundice (one month, IQR 1–1) when
Table 2. Presenting complaints, diagnostic delay and stage at diagnosis.
Jaundice Incidental Diabetes Other Weight loss Pain Total
Median delay 1 (1–1) – 4 (3–9) 1 (1–3.5) 4 (2–8) 2 (1–4)
Resectable 36 (46.8%) 11 (37.9%) 12 (26.7%) 8 (30.8%) 49 (27.6%) 28 (23.5%) 144
Borderline/locally
advanced
24 (31.1%) 9 (31%) 17 (37.7%) 8 (30.8%) 52 (29.2%) 30 (25.2%) 140
Metastatic 17 (22.1%) 9 (31%) 16 (35.6%) 10 (38.4%) 77 (43.2%) 61 (51.3%) 190
Totala 77 29 45 26 178 119 474
Data are expressed as number (%) or as median (interquartile range).
aDisease stage was deemed uncertain in three cases.
Table 1. Characteristics of the 477 pancreatic cancer cases by
disease stage at diagnosis and risk factors.
Mean age at diagnosis (years) 68 (11.3)
Male sex 245/477 (51.4%)
Female sex 232/477 (48.6%)
Disease stage at diagnosisa
Resectable 144/474 (30.4%)
Locally advanced/borderline
resectable
140/474 (29.6%)
Distant metastasis 190/474 (40%)
Factors associated with PDAC risk
1st degree family history of PDAC 39/477 (8.2%)
Ever-smokers 298/477 (62.5%)
Ever-alcohol drinker 214/477 (44.9%)
Previous diabetes mellitus 74/477 (15.5%)
BMI> 25 (kg/m2) 283/455 (62.2%)
Median diagnostic delay (months) 2 (1-5)
BMI: body mass index; IQR: interquartile range; PDAC: pancreatic ductal
adenocarcinoma; SD: standard deviation.
Data are expressed as number (%), as mean (SD) or as median (IQR;
25th–75th percentiles).
aDisease stage was deemed uncertain in three cases.
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compared with those presenting with pain, weight loss,
diabetes (p< 0.001 for all groups with p value set at
0.0125 with Bonferroni correction but not compared
with those reporting ‘other complaints’ (p¼ 0.03).
The median diagnostic delay was of one month (IQR
1–4) in patients with resectable disease, being signifi-
cantly shorter compared with the median of three
months (1–6) in patients with a locally advanced or
borderline resectable disease (p¼ 0.014) and of 2.5
months (1–5) in patients with distant metastases
(p¼ 0.0021 with p value set at 0.016 with Bonferroni
correction), while there was no difference between those
two latter groups (p¼ 0.924).
Association of risk factors for pancreatic cancer
with diagnostic delay
The median diagnostic delay was significantly longer in
patients with a BMI> 25 kg/m2 (three months, IQR
1–6) compared with those with a BMI25 kg/m2 (one
month, IQR 1–4; p¼ 0.0006), while all the other inves-
tigated risk factors were not associated with delay (see
Table 3). In fact, there was no difference in terms of
diagnostic delay between patients with and without
family history of PDAC, nor between ever-smokers
and never-smokers, ever-alcohol drinkers and never-
alcohol drinkers, and patients with or without previous
history of diabetes.
Factors associated with survival
During a median follow-up of eight months (IQR 4–18),
there were 369 deaths with a median survival time of
seven months (IQR 3–15). The median survival was
12.5 months (4.5–28) for patients with resectable disease,
10 months (6–16.5) for those with locally advanced dis-
ease and five months (2–11) for those with metastatic
disease. The median survival according to the first
reported complaint was 11 months (IQR 6.75–22) for
patients with an incidental diagnosis, nine months
(3–18) for patients presenting with jaundice, six
months (3–15) for those presenting with weight loss,
10 months (4–18) for those presenting with pain,
8.5 months (4–17) for those presenting with pain and
10 months (8–17) for those reporting other less
common complaints. At the Cox regression analysis
(see Table 4), factors associated with worse OS at the
univariable analysis were age at diagnosis (HR 1.02 per
year, 95% CI 1.01–1.03, p< 0.0001), metastatic disease
at diagnosis (HR 2.17, 95% CI 1.75–2.69, p< 0.0001),
pain as first presenting complaint (HR 2.24, 95% CI
1.2–4.18, p¼ 0.02) and BMI> 25 kg/m2 (HR 1.26, 94%
CI 1.01–1.56, p¼ 0.03).
At multivariable analysis, increasing age (HR 1.027
per year, 95% CI 1.01–1.03; p< 0,0001), metastatic dis-
ease at diagnosis (HR 2.12, 95% CI 1.69–2.66;
p< 0.0001) and the presence of pain as presenting
complaint (HR 1.32, 95% CI 1.06–1.65; p¼ 0.01)
were confirmed to be associated with worse OS (see
Figure 1). Notably, the diagnostic delay was not asso-
ciated with OS. Also, there was no significant correl-
ation between the diagnostic delay and OS (r¼ –0.0098;
95% CI –0.09–0.08, p¼ 0.82). Only 10 patients (10/577)
survived more than five years (2.1%). Their median
diagnostic delay was two months, being no different
from that of the whole study population. Four patients
presented with jaundice, four patients with weight
loss and two patients with diabetes. We could not iden-
tify factors associated with this particularly favourable
outcome. We also investigated the possible association
between diagnostic delay and survival in the Cox regres-
sion analysis in the three subgroups of patients with dif-
ferent disease stage at diagnosis and this resulted in no
association with survival either in the 144 patients with
resectable disease (HR 1.00; 95% 0.96–1.04; p¼ 0.84), in
the 140 patients with locally advanced (HR 0.98; 95%
CI 0.94–1.02; p¼ 0.54), or in the 190 patients with meta-
static disease (HR 0.99; 95% CI 0.96–1.02).
Discussion
Given the high mortality rate of PDAC, the reduction
of the delay between the very first clinical complaint
and diagnosis and treatment is considered a critical
issue. Attempts to increase the awareness of the popu-
lation and of primary care physicians with regard to the
most common symptoms and signs of the disease have
been increasingly made.10,15 However, whether such a
policy can effectively lead to diagnosis at an earlier
stage and to an increase in survival is unclear.
Table 3. Risk factors for pancreatic ductal adenocarcinoma (PDAC)
and their association with the diagnostic delay.
Risk factor
Diagnostic
delay p Value
BMI> 25 3 (1–6) 0.0006
BMI 25 1 (1–4)
PDAC FD family history 3 (1–4) 0.28
No PDAC FD family history 2 (1–5)
Ever smoker 2 (1–6) 0.63
Never smoker 2 (1–5)
Ever alcohol 2 (1–6) 0.06
Never alcohol 2 (1–4)
Previous diabetes 2 (1–5) 0.62
No diabetes 2 (1–5)
Data are expressed as median (interquartile range).
BMI: body mass index; FD: first degree.
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In the present study, the association between pre-
senting complaints caused by the disease, the diagnostic
delay, risk factors and outcome of consecutive patients
with PDAC were investigated.
The study population included 477 patients, 40%
with metastatic disease, 30% with locally advanced/bor-
derline resectable disease and 30% with resectable dis-
ease at diagnosis. The median diagnostic delay between
the very first complaint that patients recalled and diag-
nosis was two months. The commonest presenting com-
plaint was weight loss which was reported by 37% of
patients, followed by pain (25%) and jaundice (16%).
New-onset diabetes was the first sign of the disease in
9% of patients and the diagnosis was incidental in only
6% of cases. These results suggest that most initial com-
plaints associated with PDAC are unspecific, as the most
specific and alarming sign, jaundice, was reported as ini-
tial complaint by only 16% of patients.
The primary aim of the study was to investigate
whether the different presenting complaints were asso-
ciated with different diagnostic delays and, hence, with
different stages of disease and survival. It is, indeed,
unclear whether shortening the window from the first
presenting complaint to the diagnosis results in better
clinical outcomes. Interestingly, while (as expected)
some presenting complaints such as jaundice were asso-
ciated with a significantly shorter diagnostic delay and
with a lower rate of advanced disease at diagnosis, the
overall survival of patients presenting with jaundice
was no longer than that observed in other subgroups.
The longest diagnostic delays were observed in patients
reporting new-onset diabetes and weight loss with
significant differences compared with jaundice, with a
somehow intermediate interval when pain was the first
complaint. These differences were not unexpected and
similar findings have been reported by others. Porta
and colleagues17 investigated 185 consecutively enrolled
PDAC patients and reported that an increased symp-
tom-to-diagnosis interval was associated with a more
advanced stage at diagnosis and that patients with jaun-
dice more often had localised disease. However, they did
not investigate the survival of patients after diagnosis.
Walter et al.15 reported that there was only a non-
significant difference in the diagnostic interval from the
first symptom to diagnosis comparing patients without
(mean delay 108 days) or with metastatic disease (mean
delay 136 days; p¼ 0.2) at diagnosis. Also, Apollos and
colleagues9 found that delays due to pre-diagnostic
investigations for unspecific symptoms were not asso-
ciated with worse survival.
The secondary aim of the present study was to
investigate the association between the most common
factors linked with the risk of developing PDAC, such
as smoking, overweight, alcohol consumption, first
degree family history of PDAC and previous history
of diabetes, and the diagnostic delay and prognosis.
Notably, overweight patients were found to have a
longer diagnostic delay compared with those with
normal weight. None of the other risk factors was asso-
ciated with the diagnostic delay. This is, to the best of
our knowledge, the first attempt to investigate this asso-
ciation, thus interpretation of these findings can only be
speculative. It is possible both that overweight patients
might take more time to seek medical attention for
Table 4. Cox-regression analysis for factors associated with worse overall survival.
Factor
Univariable analysis
HR (95% CI; p value)
Multivariable analysis
HR (95% CI; p value)
Male sex 1.09 (0.89–1.34; p¼ 0.39) –
Age (per increasing year) 1.024 (1.01–1.03; p< 0.0001) 1.027 (1.01–1.03; p< 0,0001)
Metastatic disease at diagnosis 2.17 (1.75–2.69; p< 0.0001) 2.12 (1.69–2.66; p< 0.0001)
CA19.9> 37 1.25 (0.92–1.70; p¼ 0.14) –
Jaundice 1.01 (0.82–1.24; p¼ 0.92) –
Weight loss 1.21 (0.97–1.49; p¼ 0.07) –
Pain 2.24 (1.20–4.18; p¼ 0.02) 1.32 (1.06–1.65; p¼ 0.01)
New onset diabetes 0.96 (0.73–1.28; p¼ 0.82) –
Incidental 0.74 (0.47–1.14; p¼ 0.16) –
1st degree family history of PDAC 1.01 (0.70–1.47; p¼ 0.92) –
Ever-smoker 0.91 (0.74–1.12; p¼ 0.40) –
Ever-alcohol drinker 0.90 (0.73–1.10; p¼ 0.32) –
Previous diabetes mellitus 1.27 (0.92–1.69; p¼ 0.10) –
BMI> 25 (kg/m2) 1.26 (1.01–1.56; p¼ 0.03) 1.22 (0.98–1.51; p¼ 0.07)
Diagnostic delay (per month) 1.004 (0.98–1.02; p¼ 0.69) –
BMI: body mass index; CI: confidence interval; HR: hazard ratio; PDAC: pancreatic ductal adenocarcinoma.
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Figure 1. Kaplan–Meier curves highlighting the association of worse overall survival with (a) pain as first presenting complaint, (b) body
mass index (BMI)>25 and (c) metastatic stage.
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symptoms such as weight loss, abdominal pain and dia-
betes or that physicians might consider the symptoms
with less promptness in overweight subjects. Also,
trans-abdominal ultrasonography that is commonly
performed as first-line investigation might have limited
accuracy in overweight patients. As we have no data
on the composition of the total diagnostic delay into
the ‘patient interval’ (time from very first complaint
to first presentation to a physician) and the ‘health
system interval’ (time from first presentation and final
diagnosis) we can only hypothesise that all of these
factors might have some relevance. Notably, a
BMI> 25 before symptoms onset was also a borderline
significant factor associated with worse survival.
The reduction of the delay between the very first
complaint reported by the patient and the diagnosis is
based upon the ultimate goal of prolonging survival.
Interestingly, in the present cohort of 477 patients,
the factors associated with survival at the multivariable
regression analysis were metastatic disease at diagnosis
(HR 2.1), age at diagnosis (HR 1.02 per year) and pain
as first presenting complaint (HR 1.3), while none of
the other investigated factors, including the diagnostic
delay, influenced survival. Pain is a frequent symptom
in PDAC patients. It has a multifactorial genesis, deriv-
ing both from mechanical obstruction of the pancreatic
duct by the tumour mass and by its direct contact with
nerve plexus and by a specific form of neuropathic
pain.18 Pain might be associated with a worse prognosis
either because it is caused by the retropancreatic exten-
sion of the tumour or because neuroinvasion is an inde-
pendent factor associated with worse prognosis.19
Our finding that the association between diagnostic
delay and survival was not confirmed is not totally
unexpected. Whether a decrease in the diagnostic
delay from first complaint to diagnosis might help
improving the prognosis of PDAC patients is, indeed,
a debated issue. Gobbi and colleagues12 investigated
the association between survival and diagnostic delay
in 147 patients with PDAC and found that time to
diagnosis had an influence on survival. On the contrary,
Apollos et al.9 reported that delays caused by pre-
diagnostic investigations due to unspecific gastrointes-
tinal complaints did not appear to contribute to the
poor prognosis of pancreatic cancer in 153 patients.
Similar findings were reported by Jooste et al.20 who
examined the prognosis of 345 PDAC patients and
found that, similarly to what we found, jaundice and
the absence of metastasis were associated with a shorter
diagnostic delay. However, when they performed a
survival analysis on 298 patients, after adjustment for
other factors, especially disease stage, delay was not
associated with prognosis.
In another very recent study, Suzuky et al.21
reported data on detection-to-diagnosis and
diagnosis-to-treatment waiting times of 149 PDAC
patients, finding that these intervals have no influence
on the prognosis.
The present study has several strengths. It is by far
the largest study on the topic, examining 477 consecu-
tively enrolled PDAC patients seen in one centre, with
available data on presenting complaints, disease
features and prognosis. Also, it is the first study to
investigate the possible influence of factors associated
with an increased risk of pancreatic cancer both on the
diagnostic delay and on the prognosis of the disease.
Among the study weaknesses is its retrospective
nature, with comparisons that can only be done in an
indirect manner, its design that does not allow a con-
clusion on the mechanisms of the observed associ-
ations, and the lack of a distinction of the total delay
between the ‘patient interval’ (time from very first com-
plaint to first presentation to a physician) and the
‘health system interval’ (time from first presentation
and final diagnosis). Also, regarding the survival ana-
lysis, we could not analyse the interval from diagnosis
to actual time of treatment initiation or the type of
treatment due to lack of data. However, as the study
was of a single centre with a certain homogeneity of
treatment according to stage, we believe it is unlikely
that this variable might be a bias for the present results.
At any rate, as the study enrolment took place over a
long time-span between 2005–2018, during which novel
intensified chemotherapy regimens became available,
it would have been interesting to evaluate whether
the effect of diagnostic delay on prognosis is different
in patients that received these novel treatments.
Unfortunately, the analysis of the association between
symptoms and signs, diagnostic delay and specific treat-
ments was not possible due to lack of data and is
beyond the scope of this article. Finally, the present
results should be considered with caution as, although
use of the first complaint is an adequate approach to
understanding the presentation of these patients, this
can be difficult to interpret in clinical practice, and the
rejection of the hypothesis of a significant association
between diagnostic delay and survival in the present ana-
lysis does not mean that this association is absent.
The present results fit well with the common feeling
of experts, as recently suggested by a survey on different
cancer types listing PDAC among tumours for which a
mortality benefit from expedited diagnosis of symptom-
atic cases seems unlikely.22 PDAC is a lethal disease
because, in most cases, the disease has spread to meta-
static sites either macroscopically or microscopically
at the time of the first complaint, posing a strong
rationale for a more diffuse use of chemotherapy even
in resectable cases.23 In the past few years, it has been
postulated that as patients with PDAC present to their
primary care physicians multiple times during the year
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before the diagnosis, and sometimes with unique symp-
toms and signs, specific tools to help primary care phys-
icians decisions or use of screening biomarkers might
result in early diagnosis and survival benefits.24 In
terms of health policies and research priorities, our
findings might instead support the need for primary
prevention strategies tackling factors such as smoking,
overweight and excessive alcohol intake, and further
research on optimization of treatments. Also, as
recent findings report a non-negligible rate of germline
mutations in sporadic PDAC cases,25 it is possible that
in the future there will be an increase in the numbers of
subjects with an early diagnosis thanks to surveillance
protocols that seem to guarantee increased survival.26
Although the present results should be considered with
caution given the many intrinsic limitations, they suggest
that prevention might still be more rewarding in the case
of pancreatic cancer than relying on complaints for an
early diagnosis which is rarely early enough.
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